Marco Durante Selected Research

Ions

10/2022	FLASH with carbon ions: Tumor control, normal tissue sparing, and distal metastasis in a mouse osteosarcoma model.
8/2022	Modeling secondary cancer risk ratios for proton versus carbon ion beam therapy: A comparative study based on the local effect model.
8/2021	What can space radiation protection learn from radiation oncology?
1/2021	Reduction of Lung Metastases in a Mouse Osteosarcoma Model Treated With Carbon Ions and Immune Checkpoint Inhibitors.
1/2021	Failla Memorial Lecture: The Many Facets of Heavy-Ion Science.
1/2020	Particle therapy in Europe.
1/2018	Characterizing the Potency and Impact of Carbon Ion Therapy in a Primary Mouse Model of Soft Tissue Sarcoma.
1/2017	Differential Impact of Single-Dose Fe Ion and X-Ray Irradiation on Endothelial Cell Transcriptomic and Proteomic Responses.
9/2016	In silico comparison of photons versus carbon ions in single fraction therapy of lung cancer.
1/2016	Efficient Rejoining of DNA Double-Strand Breaks despite Increased Cell-Killing Effectiveness following Spread-Out Bragg Peak Carbon-Ion Irradiation.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Marco Durante Research Topics

Disease

75	Neoplasms (Cancer) 10/2022 - 01/2002
11	Chromosome Aberrations (Chromosome Abnormalities) 01/2018 - 12/2002
6	Hypoxia (Hypoxemia) 01/2021 - 07/2013
5	Prostatic Neoplasms (Prostate Cancer) 08/2022 - 04/2010
5	Cardiac Arrhythmias (Arrythmia) 01/2021 - 04/2015
4	Neoplasm Metastasis (Metastasis) 10/2022 - 12/2020
4	Breast Neoplasms (Breast Cancer) 01/2021 - 11/2003
4	Second Primary Neoplasms (Neoplasms, Second) 10/2020 - 06/2011
3	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2021 - 01/2018
3	Cardiovascular Diseases (Cardiovascular Disease) 01/2021 - 01/2016
3	Lung Neoplasms (Lung Cancer) 01/2018 - 06/2004
3	Atrial Fibrillation 03/2016 - 04/2012
3	Chordoma 02/2015 - 11/2010
2	Osteosarcoma (Osteogenic Sarcoma) 10/2022 - 01/2021
2	Necrosis 10/2021 - 01/2021
2	Brain Neoplasms (Brain Tumor) 01/2020 - 05/2013
2	Sarcoma (Soft Tissue Sarcoma) 01/2018 - 02/2015
2	Carcinoma (Carcinomatosis) 02/2016 - 01/2015
2	Glioblastoma (Glioblastoma Multiforme) 01/2016 - 06/2013
2	Pancreatic Neoplasms (Pancreatic Cancer) 02/2015 - 01/2015
1	Brain Edema (Cerebral Edema) 10/2021
1	Cardiotoxicity 01/2021
1	Pericardial Effusion 01/2021
1	Esophageal Neoplasms (Esophageal Cancer) 03/2020
1	Alopecia (Baldness) 01/2020
1	Radiodermatitis 01/2020
1	Dermatitis 01/2020
1	Genomic Instability 01/2020
1	Heart Diseases (Heart Disease) 01/2019
1	Radiation Pneumonitis 01/2019
1	Rupture 01/2018
1	Hodgkin Disease (Hodgkin's Disease) 05/2016
1	Neuroblastoma 01/2016
1	Leukemia 07/2015
1	Rectal Neoplasms (Rectal Cancer) 02/2015
1	Fibrosis (Cirrhosis) 01/2015
1	Chromosomal Instability (Chromosome Stability) 01/2015
1	Radiation Fibrosis Syndrome (Radiation Fibrosis) 01/2015
1	Liver Neoplasms (Liver Cancer) 05/2014
1	Chromosome Inversion (Chromosomal Inversion) 11/2013
1	Ataxia Telangiectasia (Louis Bar Syndrome) 07/2013
1	Macular Degeneration (Age-Related Maculopathy) 04/2012
1	Trigeminal Neuralgia (Tic Douloureux) 04/2012
1	Epilepsy (Aura) 04/2012
1	Carcinogenesis 08/2011

Drug/Important Bio-Agent (IBA)

30	IonsIBA 10/2022 - 12/2002
29	CarbonIBA 10/2022 - 06/2004
14	Protons (Proton)IBA 08/2022 - 04/2006
13	Biological ProductsIBA 10/2021 - 01/2008
5	Oxygen (Dioxygen)IBA 01/2021 - 07/2013
5	DNA (Deoxyribonucleic Acid)IBA 01/2020 - 08/2011
2	HeliumIBA 01/2022 - 04/2016
2	VaccinesIBA 01/2021 - 01/2017
2	Proteins (Proteins, Gene)FDA Link 11/2018 - 01/2015
2	Biomarkers (Surrogate Marker)IBA 07/2015 - 10/2005
2	IronIBA 10/2003 - 12/2002
2	UraniumIBA 01/2003 - 01/2002
1	salicylhydroxamic acid (SHAM)IBA 10/2022
1	ProteomeIBA 01/2021
1	cabozantinibIBA 01/2021
1	NoxaeIBA 01/2021
1	Immune Checkpoint InhibitorsIBA 01/2021
1	CytokinesIBA 03/2020
1	1,2- di- (4- sulfamidophenyl)- 4- butylpyrazolidine- 3,5- dione (DSB)IBA 01/2020
1	RNA (Ribonucleic Acid)IBA 11/2018
1	MicroRNAs (MicroRNA)IBA 11/2018
1	serum P-component (CIt)IBA 01/2018
1	InterferonsIBA 01/2018
1	2- cyclohexylidenhydrazo- 4- phenyl- thiazoleIBA 01/2016
1	Cytostatic AgentsIBA 01/2016
1	AnionsIBA 01/2015
1	Superoxides (Superoxide)IBA 01/2015
1	Dinoprostone (PGE2)FDA Link 01/2015
1	Peptide Hydrolases (Proteases)FDA Link 01/2015
1	Caspase 3 (Caspase-3)IBA 01/2015
1	dihydroethidiumIBA 01/2015
1	Fluorescent Dyes (Fluorescent Probes)IBA 01/2015
1	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2015
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2015
1	Cytotoxins (Cytolysins)IBA 01/2014
1	Phosphotransferases (Kinase)IBA 07/2013
1	DNA-Activated Protein KinaseIBA 07/2013
1	Temozolomide (Temodar)FDA LinkGeneric 06/2013
1	PlutoniumIBA 06/2002

Therapy/Procedure

45	Therapeutics 08/2022 - 01/2010
41	Radiotherapy 03/2022 - 11/2003
9	Proton Therapy 01/2022 - 10/2012
7	Immunotherapy 01/2022 - 01/2017
6	Heavy Ion Radiotherapy 01/2021 - 06/2004
6	Drug Therapy (Chemotherapy) 01/2019 - 01/2015
3	Catheter Ablation 01/2019 - 04/2012
2	Synchrotrons 01/2021 - 12/2002
2	Catheters 03/2016 - 04/2015
1	Image-Guided Radiotherapy 02/2016
1	Artificial Organs (Artificial Organ) 02/2015
1	Precision Medicine 01/2015
1	Denervation 04/2012
1	Segmental Mastectomy (Lumpectomy) 11/2003